JP2000511425A5 - - Google Patents

Download PDF

Info

Publication number
JP2000511425A5
JP2000511425A5 JP1997543071A JP54307197A JP2000511425A5 JP 2000511425 A5 JP2000511425 A5 JP 2000511425A5 JP 1997543071 A JP1997543071 A JP 1997543071A JP 54307197 A JP54307197 A JP 54307197A JP 2000511425 A5 JP2000511425 A5 JP 2000511425A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1997543071A
Other languages
English (en)
Japanese (ja)
Other versions
JP4318752B2 (ja
JP2000511425A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US1997/009610 external-priority patent/WO1997045450A1/en
Publication of JP2000511425A publication Critical patent/JP2000511425A/ja
Publication of JP2000511425A5 publication Critical patent/JP2000511425A5/ja
Application granted granted Critical
Publication of JP4318752B2 publication Critical patent/JP4318752B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP54307197A 1996-05-31 1997-05-30 抗エンドグリンモノクローナル抗体および抗血管新生治療におけるその使用 Expired - Lifetime JP4318752B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65595396A 1996-05-31 1996-05-31
US08/655,953 1996-05-31
PCT/US1997/009610 WO1997045450A1 (en) 1996-05-31 1997-05-30 Anti-endoglin monoclonal antibodies and their use in antiangiogenic therapy

Publications (3)

Publication Number Publication Date
JP2000511425A JP2000511425A (ja) 2000-09-05
JP2000511425A5 true JP2000511425A5 (enExample) 2005-01-13
JP4318752B2 JP4318752B2 (ja) 2009-08-26

Family

ID=24631047

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54307197A Expired - Lifetime JP4318752B2 (ja) 1996-05-31 1997-05-30 抗エンドグリンモノクローナル抗体および抗血管新生治療におけるその使用

Country Status (8)

Country Link
US (2) US5928641A (enExample)
EP (1) EP0938505B1 (enExample)
JP (1) JP4318752B2 (enExample)
AT (1) ATE214075T1 (enExample)
CA (1) CA2256413C (enExample)
DE (1) DE69710911T2 (enExample)
ES (1) ES2169864T3 (enExample)
WO (1) WO1997045450A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6749853B1 (en) 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
DE19845798A1 (de) * 1998-09-29 2000-04-13 Schering Ag Verwendung von Neoangiogenese-Markern für Diagnose und Therapie von Tumoren, diese enthaltende Mittel, sowie Verfahren zu deren Herstellung
EP1150701A4 (en) * 1999-01-22 2003-03-26 Burnham Inst TARGETING PRO-APOPTOTIC CONJUGATES AND METHODS FOR USE THEREOF
DE60135633D1 (de) * 2000-02-10 2008-10-16 Massachusetts Eye & Ear Infirm Photodynamische therapie zur behandlung von augenerkrankungen
AU2006203034B2 (en) * 2000-02-10 2006-09-07 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
DE10043481A1 (de) * 2000-09-04 2002-04-11 Vectron Therapeutics Ag Imt Humaner Antikörper gegen Endoglin (CD105) und seine Verwendung
JP2003021631A (ja) * 2001-05-10 2003-01-24 Chugai Pharmaceut Co Ltd 骨転移抑制剤のスクリーニング方法
CA2461905A1 (en) * 2001-09-27 2003-04-10 Board Of Regents, The University Of Texas System Combined compositions and methods for tumor vasculature coagulation and treatment
US20050106667A1 (en) * 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
US7758859B2 (en) 2003-08-01 2010-07-20 Genentech, Inc. Anti-VEGF antibodies
WO2005044853A2 (en) * 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
AP2012006644A0 (en) * 2003-08-01 2012-12-31 Genentech Inc Anti-VEGF antibodies
EP1533617A1 (en) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
US20060052286A1 (en) * 2004-08-13 2006-03-09 Yale University Factor VII conjugates for selectively treating neovascularization disorders
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
US20060067937A1 (en) * 2004-09-24 2006-03-30 Karumanchi S A Methods of diagnosing and treating complications of pregnancy
BRPI0519096A2 (pt) * 2004-12-15 2008-12-23 Beth Israel Hospital Ácidos nuclÉicos e polipeptÍdeos éteis para o diagnàstico e tratamento de complicaÇÕes na gravidez
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
US8642031B2 (en) 2006-11-02 2014-02-04 Acceleron Pharma, Inc. Antagonists of BMP9, BMP10, ALK1 and other ALK1 ligands, and uses thereof
KR101581961B1 (ko) 2006-11-02 2016-01-04 악셀레론 파마 인코포레이티드 Alk1 수용체 및 리간드 길항제 및 그의 용도
US10059756B2 (en) 2006-11-02 2018-08-28 Acceleron Pharma Inc. Compositions comprising ALK1-ECD protein
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
KR20180029111A (ko) 2008-05-02 2018-03-19 악셀레론 파마 인코포레이티드 혈관신생 및 혈관주위세포 적용범위의 조정을 위한 alk1 길항제 기재의 방법 및 조성물
US20100082438A1 (en) * 2008-10-01 2010-04-01 Ronnie Jack Garmon Methods and systems for customer performance scoring
EP3281637A1 (en) * 2009-08-17 2018-02-14 Tracon Pharmaceuticals, Inc. Combination therapy of cancer with anti-endoglin antibodies and anti-vegf agents
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
TWI488642B (zh) * 2009-12-09 2015-06-21 Bayer Schering Pharma Ag 抗-C4.4a抗體及其用途
CA2827952A1 (en) 2011-02-23 2012-11-01 Health Research, Inc. Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin
US9255595B2 (en) * 2011-04-29 2016-02-09 Bae Systems Information And Electronic Systems Integration Inc. Optical dome bezel
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
ES2710203T3 (es) 2013-06-14 2019-04-23 Agilent Technologies Inc Sistema y método para facilitar la clasificación manual de objetos
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
US10155820B2 (en) 2014-11-12 2018-12-18 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
US10072075B2 (en) 2015-09-23 2018-09-11 Genentech, Inc. Optimized variants of anti-VEGF antibodies and methods of treatment thereof by reducing or inhibiting angiogenesis
RU2607029C1 (ru) * 2015-10-20 2017-01-10 ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ "РОССИЙСКИЙ НАУЧНЫЙ ЦЕНТР РАДИОЛОГИИ И ХИРУРГИЧЕСКИХ ТЕХНОЛОГИЙ" МИНИСТЕРСТВА ЗДРАВООХРАНЕНИЯ РОССИЙСКОЙ ФЕДЕРАЦИИ / ФГБУ "РНЦРХТ" Минздрава России ШТАММ ГИБРИДНЫХ КУЛЬТИВИРУЕМЫХ КЛЕТОК ЖИВОТНЫХ Mus musculus L. - EN-4C9 - ПРОДУЦЕНТ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ ПРОТИВ ЭНДОГЛИНА (CD105) ЧЕЛОВЕКА
CN106928359B (zh) * 2015-12-30 2020-10-13 广西医科大学 一种CD105纳米抗体Nb59
CN106928355B (zh) * 2015-12-30 2020-09-29 广西医科大学 一种CD105纳米抗体Nb184
GB2566221B (en) 2016-06-24 2021-08-04 Univ South Carolina Inhibin as targetable regulators of angiogenesis
EP3900733A1 (en) 2020-04-24 2021-10-27 Derma Innovate S.L. Src kinase activators and eng function inhibitors as enhancers of skin homeostasis/regeneration and hair growth
CN115991773B (zh) * 2022-08-15 2023-11-17 营龄(武汉)生物科技有限公司 一种含有人血白蛋白的药物组合物
CN116063496B (zh) * 2022-08-15 2023-10-24 营龄(武汉)生物科技有限公司 载药的人血白蛋白联合单克隆抗体在制备药物组合物中的用途
WO2026017807A1 (en) 2024-07-18 2026-01-22 Beech Biotech Sa Compositions and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94389A0 (en) * 1989-06-01 1991-03-10 Health Research Inc Monoclonal antibody reactive to a unique antigen widely present on various human leukemia and lymphoma cells and method of using same for diagnosis and treatment
US5776427A (en) * 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2000501771A5 (enExample)
JP2001506876A5 (enExample)
JP2001503840A5 (enExample)
JP2000500076A5 (enExample)
JP2002514060A5 (enExample)
JP2000506111A5 (enExample)
JP2001509135A5 (enExample)
JP2000500055A5 (enExample)
JP2000500026A5 (enExample)
JP2000502472A5 (enExample)
JP2000501825A5 (enExample)
JP2000502485A5 (enExample)
JP2000502425A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000511425A5 (enExample)
JP2000503848A5 (enExample)
JP2000502570A5 (enExample)
JP2000501876A5 (enExample)
JP2001527686A5 (enExample)
JP2000505908A5 (enExample)
JP2000501744A5 (enExample)
JP2000502316A5 (enExample)
JP2000502714A5 (enExample)